<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39404761</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1971</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>Pediatric cardiology</Title><ISOAbbreviation>Pediatr Cardiol</ISOAbbreviation></Journal><ArticleTitle>Myocarditis and Pericarditis are Temporally Associated with BNT162b2 COVID-19 Vaccine in Adolescents: A Systematic Review and Meta-analysis.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00246-024-03618-2</ELocationID><Abstract><AbstractText>The incidence of myocarditis and pericarditis has been documented in adolescents after COVID-19 vaccinations. This study aims to assess the risk of myopericarditis in adolescents following COVID-19 vaccination, using a meta-analysis of the published cases. We performed a comprehensive literature search of the following databases on July 5, 2023: MEDLINE, EMBASE, PubMed, and the Cochrane Library. We performed a meta-analysis using a random-effects model to estimate the incidence of myopericarditis per million of administered COVID-19 vaccine doses or COVID-19 infections. A total of 33 studies were included in the meta-analysis. The incidence of myopericarditis per million COVID-19 infections (1583.9 cases, 95% CI 751.8-2713.8) was approximately 42 times higher than that for COVID-19 vaccine administrations (37.6 cases, 95% CI 24.2-53.8). The risk of myopericarditis after COVID-19 vaccination was particularly high among the 16-19 age group (39.5 cases per million, 95% CI 25.8-56.0), males (43.1 cases per million, 95% CI 21.6-71.9), and those who received the second dose (47.7 cases per million, 95% CI 22.2-82.2). There were no significant differences in the incidence of myopericarditis per million COVID-19 vaccine administrations between Europe, the Western Pacific, and the Americas (p = 0.51). Adolescents faced a potential risk of myopericarditis after COVID-19 vaccination, but this risk is less harmful than that of myopericarditis following COVID-19 infection.</AbstractText><CopyrightInformation>© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Choi</LastName><ForeName>Yongyeon</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Graduate School of Urban Public Health, University of Seoul, 163 Seoulsiripdae-ro, Dongdaemun-gu, Seoul, 02504, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Lee</LastName><ForeName>Jue Seong</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Korea University Anam Hospital, 73 Goryodae-ro, Seongbuk-gu, Seoul, 02841, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Korea University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choe</LastName><ForeName>Young June</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Korea University Anam Hospital, 73 Goryodae-ro, Seongbuk-gu, Seoul, 02841, Republic of Korea. choey@korea.ac.kr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Korea University College of Medicine, Seoul, Korea. choey@korea.ac.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Hyeran</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Graduate School of Urban Public Health, University of Seoul, 163 Seoulsiripdae-ro, Dongdaemun-gu, Seoul, 02504, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Yoonsun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Korea University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Korea University Guro Hospital, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Seung Hwan</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Immunization Safety Group, COVID-19 Vaccination Task Force, Korea Disease Control and Prevention Agency, Cheongju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Myung-Jae</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Immunization Safety Group, COVID-19 Vaccination Task Force, Korea Disease Control and Prevention Agency, Cheongju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>HyoSug</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Immunization Safety Group, COVID-19 Vaccination Task Force, Korea Disease Control and Prevention Agency, Cheongju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Na</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Immunization Safety Group, COVID-19 Vaccination Task Force, Korea Disease Control and Prevention Agency, Cheongju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jong Hee</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Immunization Safety Group, COVID-19 Vaccination Task Force, Korea Disease Control and Prevention Agency, Cheongju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Hyun Mi</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahn</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, The Catholic University of Korea Yeouido St. Mary's Hospital, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seo</LastName><ForeName>Kyoungsan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>College of Nursing, Chungnam National University, Daejeon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Sangshin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Graduate School of Urban Public Health, University of Seoul, 163 Seoulsiripdae-ro, Dongdaemun-gu, Seoul, 02504, Republic of Korea. spark@uos.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pediatr Cardiol</MedlineTA><NlmUniqueID>8003849</NlmUniqueID><ISSNLinking>0172-0643</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adolescent</Keyword><Keyword MajorTopicYN="N">COVID-19 vaccines</Keyword><Keyword MajorTopicYN="N">Global health</Keyword><Keyword MajorTopicYN="N">Myocarditis</Keyword><Keyword MajorTopicYN="N">Pericarditis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>11</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39404761</ArticleId><ArticleId IdType="doi">10.1007/s00246-024-03618-2</ArticleId><ArticleId IdType="pii">10.1007/s00246-024-03618-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jee Y (2020) WHO international health regulations emergency committee for the COVID-19 outbreak. Epidemiol Health 42:e2020013</Citation><ArticleIdList><ArticleId IdType="doi">10.4178/epih.e2020013</ArticleId><ArticleId IdType="pubmed">32192278</ArticleId><ArticleId IdType="pmc">7285442</ArticleId></ArticleIdList></Reference><Reference><Citation>Berlin DA, Gulick RM, Martinez FJ (2020) Severe covid-19. N Engl J Med 383:2451–2460</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMcp2009575</ArticleId><ArticleId IdType="pubmed">32412710</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC (2022) Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis 22:1293–1302</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00320-6</ArticleId><ArticleId IdType="pubmed">35753318</ArticleId><ArticleId IdType="pmc">9225255</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidecker B, Dagan N, Balicer R et al (2022) Myocarditis following COVID-19 vaccine: incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus document supported by the Heart Failure Association of the European Society of Cardiology (ESC) and the ESC Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail 24:2000–2018</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.2669</ArticleId><ArticleId IdType="pubmed">36065751</ArticleId></ArticleIdList></Reference><Reference><Citation>Witberg G, Barda N, Hoss S et al (2021) Myocarditis after Covid-19 vaccination in a large health care organization. N Engl J Med 385:2132–2139</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2110737</ArticleId><ArticleId IdType="pubmed">34614329</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozkurt B, Kamat I, Hotez PJ (2021) Myocarditis with COVID-19 mRNA vaccines. Circulation 144:471–484</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.121.056135</ArticleId><ArticleId IdType="pubmed">34281357</ArticleId><ArticleId IdType="pmc">8340726</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoy D, Brooks P, Woolf A et al (2012) Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol 65:934–939</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2011.11.014</ArticleId><ArticleId IdType="pubmed">22742910</ArticleId></ArticleIdList></Reference><Reference><Citation>Mevorach D, Anis E, Cedar N et al (2021) Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel. N Engl J Med 385:2140–2149</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2109730</ArticleId><ArticleId IdType="pubmed">34614328</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood N, Lopez LK, Glover C, et al. Active safety surveillance of COVID-19 mRNA vaccines in children aged 5–15 years in Australia. medRxiv 2022:2022.07. 19.22277827.</Citation></Reference><Reference><Citation>Lee CW, Sa S, Hong M, Kim J, Shim SR, Han HW (2022) Adverse events and safety profile of the COVID-19 vaccines in adolescents: safety monitoring for adverse events using real-world data. Vaccines (Basel). https://doi.org/10.3390/vaccines10050744</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10050744</ArticleId><ArticleId IdType="pubmed">36679923</ArticleId><ArticleId IdType="pmc">9499217</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai FTT, Chua GT, Chan EWW et al (2022) Adverse events of special interest following the use of BNT162b2 in adolescents: a population-based retrospective cohort study. Emerg Microbes Infect 11:885–893</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2050952</ArticleId><ArticleId IdType="pubmed">35254219</ArticleId><ArticleId IdType="pmc">8942549</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Heo Y, Seo SY, Lim DS, Cho E, Lee YK (2022) Adverse events of the Pfizer-BioNTech COVID-19 vaccine in Korean children and adolescents aged 5 to 17 years. Osong Public Health Res Perspect 13:382–390</Citation><ArticleIdList><ArticleId IdType="doi">10.24171/j.phrp.2022.0233</ArticleId><ArticleId IdType="pubmed">36328243</ArticleId><ArticleId IdType="pmc">9633262</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Vu S, Bertrand M, Jabagi MJ et al (2022) Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines. Nat Commun 13:3633</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-31401-5</ArticleId><ArticleId IdType="pubmed">35752614</ArticleId><ArticleId IdType="pmc">9233673</ArticleId></ArticleIdList></Reference><Reference><Citation>Krug A, Stevenson J, Høeg TB (2022) BNT162b2 vaccine-associated Myo/pericarditis in adolescents: a stratified risk-benefit analysis. Eur J Clin Invest 52:e13759</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.13759</ArticleId><ArticleId IdType="pubmed">35156705</ArticleId><ArticleId IdType="pmc">9111575</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho JY, Kim KH, Lee N et al (2023) COVID-19 vaccination-related myocarditis: a Korean nationwide study. Eur Heart J 44:2234–2243</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehad339</ArticleId><ArticleId IdType="pubmed">37264895</ArticleId><ArticleId IdType="pmc">10290868</ArticleId></ArticleIdList></Reference><Reference><Citation>Chua GT, Kwan MYW, Chui CSL et al (2022) Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents following Comirnaty vaccination. Clin Infect Dis 75:673–681</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab989</ArticleId><ArticleId IdType="pubmed">34849657</ArticleId></ArticleIdList></Reference><Reference><Citation>Goddard K, Hanson KE, Lewis N, Weintraub E, Fireman B, Klein NP (2022) Incidence of myocarditis/pericarditis following mRNA COVID-19 vaccination among children and younger adults in the United States. Ann Intern Med 175:1169–1771</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M22-2274</ArticleId><ArticleId IdType="pubmed">36191323</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng DR, Clothier HJ, Morgan HJ et al (2022) Myocarditis and myopericarditis cases following COVID-19 mRNA vaccines administered to 12–17-year olds in Victoria. Australia BMJ Paediatr Open. https://doi.org/10.1136/bmjpo-2022-001472</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjpo-2022-001472</ArticleId><ArticleId IdType="pubmed">36053607</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Lai FTT, Chua GT et al (2022) Myocarditis following COVID-19 BNT162b2 vaccination among adolescents in Hong Kong. JAMA Pediatr 176:612–614</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2022.0101</ArticleId><ArticleId IdType="pubmed">35212709</ArticleId><ArticleId IdType="pmc">9171561</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiyovich A, Plakht Y, Witberg G et al (2022) Myocarditis following COVID-19 vaccination in adolescents: cardiac magnetic resonance imaging study. Front Cardiovasc Med 9:978592</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.978592</ArticleId><ArticleId IdType="pubmed">36277758</ArticleId><ArticleId IdType="pmc">9580007</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchan SA, Alley S, Seo CY et al (2023) Myocarditis or pericarditis events after BNT162b2 vaccination in individuals aged 12 to 17 years in Ontario. Canada JAMA Pediatr 177:410–418</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2022.6166</ArticleId><ArticleId IdType="pubmed">36848096</ArticleId></ArticleIdList></Reference><Reference><Citation>Ab Rahman N, Lim MT, Lee FY, Anak Jam EB, Peariasamy KM, Sivasampu S (2023) Myocarditis/pericarditis following vaccination with BNT162b2, CoronaVac, and ChAdOx1 among adolescent and adult in Malaysia. Vaccine X 14:100303</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvacx.2023.100303</ArticleId><ArticleId IdType="pubmed">37091730</ArticleId><ArticleId IdType="pmc">10104785</ArticleId></ArticleIdList></Reference><Reference><Citation>Naveed Z, Li J, Spencer M et al (2022) Observed versus expected rates of myocarditis after SARS-CoV-2 vaccination: a population-based cohort study. CMAJ 194:E1529–E1536</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.220676</ArticleId><ArticleId IdType="pubmed">36410749</ArticleId><ArticleId IdType="pmc">9828950</ArticleId></ArticleIdList></Reference><Reference><Citation>Matson RP, Niesen MJM, Levy ER et al (2023) Paediatric safety assessment of BNT162b2 vaccination in a multistate hospital-based electronic health record system in the USA: a retrospective analysis. Lancet Digit Health 5:e206–e216</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2589-7500(22)00253-9</ArticleId><ArticleId IdType="pubmed">36963910</ArticleId></ArticleIdList></Reference><Reference><Citation>Yap J, Tham MY, Poh J et al (2022) Pericarditis and myocarditis after COVID-19 mRNA vaccination in a nationwide setting. Ann Acad Med Singap 51:96–100</Citation><ArticleIdList><ArticleId IdType="doi">10.47102/annals-acadmedsg.2021425</ArticleId><ArticleId IdType="pubmed">35224605</ArticleId></ArticleIdList></Reference><Reference><Citation>Nygaard U, Holm M, Bohnstedt C et al (2022) Population-based incidence of myopericarditis after COVID-19 vaccination in Danish adolescents. Pediatr Infect Dis J 41:e25–e28</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000003389</ArticleId><ArticleId IdType="pubmed">34889875</ArticleId></ArticleIdList></Reference><Reference><Citation>Alami A, Krewski D, Mattison D et al (2022) Risk of myocarditis and pericarditis among young adults following mRNA COVID-19 vaccinations. Vaccines (Basel). https://doi.org/10.3390/vaccines10050722</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10050722</ArticleId><ArticleId IdType="pubmed">35632478</ArticleId></ArticleIdList></Reference><Reference><Citation>Su WJ, Liu YL, Chang CH et al (2023) Risk of myocarditis and pericarditis following coronavirus disease 2019 messenger RNA Vaccination-A nationwide study. J Microbiol Immunol Infect 56:558–565</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2023.01.016</ArticleId><ArticleId IdType="pubmed">36804307</ArticleId><ArticleId IdType="pmc">9907782</ArticleId></ArticleIdList></Reference><Reference><Citation>Nygaard U, Holm M, Dungu KHS et al (2022) Risk of myopericarditis after COVID-19 vaccination in Danish children aged 5 to 11 Years. Pediatrics. https://doi.org/10.1542/peds.2022-057508</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2022-057508</ArticleId><ArticleId IdType="pubmed">35585684</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi H, Fukuda S, Matsukawa R et al (2023) Risks of myocarditis and pericarditis following vaccination with SARS-CoV-2 mRNA vaccines in Japan: an analysis of spontaneous reports of suspected adverse events. Ther Innov Regul Sci 57:329–342</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43441-022-00466-1</ArticleId><ArticleId IdType="pubmed">36310329</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvo F, Pariente A, Valnet-Rabier MB et al (2023) Role of spontaneous reporting in investigating the relationship between mRNA COVID-19 vaccines and myocarditis: The French perspective. Therapie 78:509–515</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.therap.2023.03.003</ArticleId><ArticleId IdType="pubmed">37012151</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonginnetra S, Tawinprai K, Niemsorn K et al (2022) Safety after BBIBP-CorV (Sinopharm) COVID-19 vaccine in adolescents aged 10–17 years in Thailand. Vaccines (Basel). https://doi.org/10.3390/vaccines10101765</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10101765</ArticleId><ArticleId IdType="pubmed">36298630</ArticleId></ArticleIdList></Reference><Reference><Citation>June Choe Y, Yi S, Hwang I et al (2022) Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents. Vaccine 40:691–694</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.12.044</ArticleId><ArticleId IdType="pubmed">35012777</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordström P, Ballin M, Nordström A (2023) Safety and effectiveness of monovalent COVID-19 mRNA vaccination and risk factors for hospitalisation caused by the omicron variant in 0.8 million adolescents: a nationwide cohort study in Sweden. PLoS Med 20:e1004127</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1004127</ArticleId><ArticleId IdType="pubmed">36802397</ArticleId><ArticleId IdType="pmc">9990916</ArticleId></ArticleIdList></Reference><Reference><Citation>Hause AM, Shay DK, Klein NP et al (2022) Safety of COVID-19 vaccination in United States children ages 5 to 11 years. Pediatrics. https://doi.org/10.1542/peds.2022-057313</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2022-057313</ArticleId><ArticleId IdType="pubmed">35581698</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu M, Wong HL, Feng Y et al (2023) Safety of the BNT162b2 COVID-19 vaccine in children aged 5 to 17 years. JAMA Pediatr 177:710–717</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2023.1440</ArticleId><ArticleId IdType="pubmed">37213095</ArticleId><ArticleId IdType="pmc">10203969</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuta T, Aizawa Y, Shoji K et al (2023) Acute and postacute clinical characteristics of Coronavirus disease 2019 in children in Japan. Pediatr Infect Dis J 42:240–246</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000003792</ArticleId><ArticleId IdType="pubmed">36730047</ArticleId></ArticleIdList></Reference><Reference><Citation>Encinosa W, Moon K, Figueroa J, Elias Y (2023) Complications, adverse drug events, high costs, and disparities in multisystem inflammatory syndrome in children vs COVID-19. JAMA Netw Open 6:e2244975</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.44975</ArticleId><ArticleId IdType="pubmed">36602804</ArticleId><ArticleId IdType="pmc">9857408</ArticleId></ArticleIdList></Reference><Reference><Citation>Boehmer TK, Kompaniyets L, Lavery AM et al (2021) Association between COVID-19 and myocarditis using hospital-based administrative data - United States, March 2020-January 2021. MMWR Morb Mortal Wkly Rep 70:1228–1232</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7035e5</ArticleId><ArticleId IdType="pubmed">34473684</ArticleId><ArticleId IdType="pmc">8422872</ArticleId></ArticleIdList></Reference><Reference><Citation>Kompaniyets L, Bull-Otterson L, Boehmer TK et al (2022) Post-COVID-19 symptoms and conditions among children and adolescents - United States, March 1, 2020-January 31, 2022. MMWR Morb Mortal Wkly Rep 71:993–999</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7131a3</ArticleId><ArticleId IdType="pubmed">35925799</ArticleId><ArticleId IdType="pmc">9368731</ArticleId></ArticleIdList></Reference><Reference><Citation>Voleti N, Reddy SP, Ssentongo P (2022) Myocarditis in SARS-CoV-2 infection vs. COVID-19 vaccination: a systematic review and meta-analysis. Front Cardiovasc Med 9:951314</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.951314</ArticleId><ArticleId IdType="pubmed">36105535</ArticleId><ArticleId IdType="pmc">9467278</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao J, Feng L, Li Y et al (2023) A systematic review and meta-analysis of the association between SARS-CoV-2 vaccination and myocarditis or pericarditis. Am J Prev Med 64:275–284</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amepre.2022.09.002</ArticleId><ArticleId IdType="pubmed">36266115</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallo K, Goede A, Mura C et al (2022) A comparative analysis of COVID-19 vaccines based on over 580,000 cases from the vaccination adverse event reporting system. Vaccines (Basel). https://doi.org/10.3390/vaccines10030408</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10030408</ArticleId><ArticleId IdType="pubmed">36560451</ArticleId></ArticleIdList></Reference><Reference><Citation>Patone M, Mei XW, Handunnetthi L et al (2021) Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med 28:410–422</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01630-0</ArticleId><ArticleId IdType="pubmed">34907393</ArticleId><ArticleId IdType="pmc">8863574</ArticleId></ArticleIdList></Reference><Reference><Citation>Katoto PDMC, Byamungu LN, Brand AS et al (2023) Systematic review and meta-analysis of myocarditis and pericarditis in adolescents following COVID-19 BNT162b2 vaccination. NPJ Vaccines. https://doi.org/10.1038/s41541-023-00681-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-023-00681-3</ArticleId><ArticleId IdType="pubmed">37296167</ArticleId><ArticleId IdType="pmc">10252172</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>